IN2014DN08398A - - Google Patents

Info

Publication number
IN2014DN08398A
IN2014DN08398A IN8398DEN2014A IN2014DN08398A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A IN 8398DEN2014 A IN8398DEN2014 A IN 8398DEN2014A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A
Authority
IN
India
Prior art keywords
biomarker
parkinson
disease
drug
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Dario Alessi
Muratul Muqit
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN08398A publication Critical patent/IN2014DN08398A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN8398DEN2014 2012-04-11 2013-04-10 IN2014DN08398A (instruction)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201206382A GB201206382D0 (en) 2012-04-11 2012-04-11 Parkinson's disease biomarker
PCT/GB2013/050926 WO2013153386A1 (en) 2012-04-11 2013-04-10 Parkinson's disease biomarker

Publications (1)

Publication Number Publication Date
IN2014DN08398A true IN2014DN08398A (instruction) 2015-05-08

Family

ID=46177150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8398DEN2014 IN2014DN08398A (instruction) 2012-04-11 2013-04-10

Country Status (5)

Country Link
US (1) US20150104806A1 (instruction)
EP (1) EP2836842A1 (instruction)
GB (1) GB201206382D0 (instruction)
IN (1) IN2014DN08398A (instruction)
WO (1) WO2013153386A1 (instruction)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9804174B2 (en) 2014-02-18 2017-10-31 Tokyo Metropolitan Institute Of Medical Science Biomarker for parkinson's disease and use thereof
WO2016179103A1 (en) * 2015-05-01 2016-11-10 National Taiwan University Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment
GB201516342D0 (en) * 2015-09-15 2015-10-28 Univ Dundee Downstream targets of PINK1
WO2017053718A2 (en) * 2015-09-23 2017-03-30 Boston Medical Center Corporation Biomarkers for the early detection of parkinson's disease
EP3661413A1 (en) * 2017-08-01 2020-06-10 Cove Bio LLC Biomarkers associated with parkinson's disease
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN113227788B (zh) * 2019-03-19 2023-11-21 中南大学湘雅医院 一种辅助诊断和治疗帕金森病的方法和试剂
WO2024081653A2 (en) * 2022-10-12 2024-04-18 Acurex Biosciences Corporation Methods of lowering miro2 to treat neurodegenerative diseases

Also Published As

Publication number Publication date
WO2013153386A1 (en) 2013-10-17
GB201206382D0 (en) 2012-05-23
US20150104806A1 (en) 2015-04-16
EP2836842A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
IN2014DN08398A (instruction)
WO2013066764A3 (en) Alzheimer's disease signature markers and methods of use
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
WO2014140254A9 (en) Improved user interface for acquistion, display and analysis of ophthalmic diagnostic data
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
WO2012173976A3 (en) Methods and apparatus for assessing activity of an organ and uses thereof
SI2900279T1 (sl) GRPR-antagonisti za detekcijo, diagnozo in zdravljenje GRPR-pozitivnega raka
HK1204544A1 (en) Methods and assessment scales for measuring wrinkle severity
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
WO2014052685A3 (en) Devices and methods for single cell analysis
HK1232289A1 (zh) 分拣蛋白作为针对情感/心境障碍的生物标记的用途
NZ729773A (en) Biomarkers for disease progression in melanoma
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
EP2983693A4 (en) SEPT4 / ARTS AS TUMOR SUPPRESSOR IN THE DIAGNOSIS, FORECASTING AND TREATMENT OF LIVER DISEASES
BR112015027249A2 (pt) método de diagnóstico de câncer
HUE037004T2 (hu) Szterolszármazékok és felhasználásuk transzformált asztrocitasejtekkel kapcsolatos betegségek vagy malignus hemopátiák kezelésére
WO2014169011A3 (en) Methods for treating immune diseases
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent